TABLE 1.
Patient and treatment characteristics
| Black | White | Hispanic | |
|---|---|---|---|
| N | 77 | 93 | 37 |
| Age at diagnosis | 61.4 | 62.4 | 60.1 |
| Age at ICI initiation | 62.8 | 64.3 | 61.1 |
| Sex | |||
| Male | 58 (75.3) | 69 (74.2) | 22 (59.5) |
| Female | 19 (24.7) | 24 (25.8) | 15 (40.5) |
| Smoking statusa | |||
| Yes | 66 (85.7) | 85 (91.4) | 24 (64.7) |
| Never smoker | 10 (13.0) | 8 (8.6) | 13 (35.1) |
| Smoker at diagnosis | 21 (27.3) | 34 (36.6) | 7 (18.9) |
| Unknown | 1 (1.3) | 0 (0) | 0 (0) |
| Alcoholb | |||
| Yes | 21 (27.3) | 39 (41.9) | 10 (27.0) |
| No | 50 (64.9) | 44 (47.3) | 26 (68.4) |
| Unknown | 6 (7.8) | 10 (10.8) | 1 (2.7) |
| Cancer | |||
| Lung | 68 (88.3) | 75 (80.6) | 31 (83.8) |
| Adenocarcinoma | 51 (75.0) | 44 (58.7) | 22 (71.0) |
| Squamous | 15 (22.1) | 21 (28.0) | 7 (22.6) |
| Small cell | 2 (2.9) | 8 (10.7) | 2 (6.5) |
| NSCLC (NOS) | 0 (0) | 2 (2.7) | 0 (0) |
| Head and neck SCC | 9 (11.7) | 18 (19.4) | 6 (16.2) |
| ECOG | |||
| 0 | 9 (11.7) | 13 (14.0) | 7 (18.9) |
| 1 | 33 (42.9) | 40 (43.0) | 19 (51.4) |
| 2 | 23 (29.9) | 27 (29.0) | 7 (18.9) |
| 3 | 3 (3.9) | 7 (7.5) | 3 (8.1) |
| 4 | 1 (1.3) | 0 (0) | 0 (0) |
| Unknown | 8 (10.4) | 6 (6.5) | 1 (2.7) |
| Number of metastasisa | |||
| 0 | 10 (13.0) | 12 (12.9) | 5 (13.5) |
| Contralateral lung only | 7 (9.0) | 4 (4.3) | 6 (16.2) |
| 1 | 20 (26.0) | 41 (44.1) | 4 (10.8) |
| 2 | 30 (39.0) | 16 (17.2) | 15 (40.5) |
| 3 | 6 (7.8) | 16 (17.2) | 4 (10.8) |
| 4+ | 4 (5.2) | 4 (4.3) | 3 (8.1) |
| Any brain metastasis | 13 (16.9) | 25 (26.9) | 13 (35.1) |
| Prior systemic therapy (all) | |||
| 0 | 19 (24.7) | 24 (25.8) | 10 (27.0) |
| 1 | 33 (42.9) | 46 (49.5) | 17 (45.9) |
| 2 | 18 (23.4) | 15 (16.1) | 5 (13.5) |
| 3 | 4 (5.2) | 4 (4.3) | 2 (5.4) |
| 4+ | 3 (3.9) | 4 (4.3) | 3 (8.1) |
| Prior systemic therapy (concurrent and adjuvant chemo excluded) | |||
| 0 | 29 (37.7) | 39 (41.9) | 17 (45.9) |
| 1 | 33 (42.9) | 41 (44.1) | 13 (35.1) |
| 2 | 10 (13.0) | 6 (6.5) | 2 (5.4) |
| 3 | 2 (2.6) | 3 (3.2) | 2 (5.4) |
| 4+ | 2 (2.6) | 4 (4.3) | 3 (8.1) |
| Concurrent chemo with ICI | |||
| Yes | 19 (24.7) | 15 (16.1) | 8 (21.6) |
| No | 58 (75.3) | 78 (83.9) | 29 (78.3) |
| ICI treatment | |||
| Nivolumab | 36 (46.8) | 47 (50.5) | 16 (43.2) |
| Pembrolizumab | 41 (59.7) | 46 (49.5) | 21 (56.8) |
| Prior radiation anywhereb | |||
| Yes | 49 (63.6) | 73 (78.5) | 22 (59.5) |
| No | 28 (36.4) | 20 (21.5) | 15 (40.5) |
| PD-L1 (NSCLC only) | |||
| 0% | 7 (10.6) | 8 (11.9) | 4 (12.9) |
| 1–49% | 17 (25.8) | 8 (11.9) | 6 (19.4) |
| >50% | 16 (24.2) | 18 (26.9) | 10 (32.3) |
| Unknown | 26 (39.4) | 41 (61.2) | 11 (35.5) |
a P < 0.05 for Hispanic vs. White.
b P < 0.05 for Black vs. White.